Mechanism of Action of the LAT1 Inhibitor Being Developed by Our Company
NEWS
-
- 2026.11.16
-
Two Abstracts on Nanvuranlat Accepted for ASCO GI 2027 ― Featuring the Global Phase III Clinical Trial “Beacon-BTC” and an Investigator-Initiated Clinical Trial in Japan ―
-
- 2026.11.04
-
J-Pharma Launches New Clinical Trial FAQ Page ― Helping Readers Better Understand Our Clinical Trials ―
-
- 2026.10.30
-
Notice of Grant approval and Commencement of the Grant-Funded Project under AMED’s GRiT Program — Grant approved for the maximum amount of JPY 1.5 billion —